9 % Braun Injektionslösung
Sponsors
Merck Sharp & Dohme LLC, Janssen Vaccines & Prevention B.V., Janssen - Cilag International, Octapharma AG, Medical University Of Vienna
Conditions
Acquired Antithrombin Deficiency (Heparin Resistance)Lung transplantationPrevention of Respiratory syncytial virus (RSV) infection in infants and children at increased risk for severe RSV diseasePrevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) diseaseWarm Autoimmune Hemolytic Anemia
Phase 2
Phase 3
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
CompletedCTIS2022-500752-39-00
Start: 2021-11-25End: 2025-06-02Target: 317Updated: 2025-06-04
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
CompletedCTIS2023-504168-40-00
Start: 2023-11-06End: 2024-07-26Target: 400Updated: 2024-06-11
Phase 3, double-blind, placebo-controlled, multicentre study on the efficacy and safety of human plasma derived antithrombin (Atenativ) in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass
Active, not recruitingCTIS2023-507560-39-00
Start: 2024-11-07Target: 34Updated: 2025-12-19